Noveris Health Sciences Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jason Birmingham
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 789 West Pender Street Vancouver BC Canada V6E 3C9
- IPO Date
- Jan 8, 2021
- Website
- noveris.health
- Similar Companies
- Business
- Mydecine Innovations Group Inc. is a Vancouver-based biotechnology company founded in 2013 and headquartered at 1075 West Georgia Street, Suite 1890, Vancouver, British Columbia, Canada, that develops next-generation psychedelic-derived therapeutics and novel molecules targeting unmet needs in mental health disorders including nicotine addiction, posttraumatic stress disorder, anxiety, depression, and related conditions; core products and pipeline candidates encompass first- and second-generation compounds such as lead candidate MYCO-005, alongside MYCO-006 and MYCO-007 which feature enhanced delivery mechanisms, safety profiles, controllability, stability, and shelf-life for psychedelic-assisted therapies, supported by partnerships like the Applied Pharmaceutical Innovation collaboration for empathogenic and entactogenic drug discovery, a five-year research agreement with Johns Hopkins University for clinical trials, and historical integrations including the 2020 acquisitions of Mindleap Health's HIPAA-compliant digital telehealth platform for remote psychedelic treatment protocols and NeuroPharm Inc. for veteran-focused psychedelic therapies; operations span North America and Europe with a focus on clinical trials, AI-paired drug chemistry, and controlled drug delivery systems. Recent developments include closing debt settlements via share issuances, implementing a share consolidation on October 6, 2025 to streamline capital structure, receiving two USPTO Notices of Allowance for the MYCO-005 and MYCO-006 patent families to bolster intellectual property protection, filing audited annual financial statements and Q1 2024 results in July 2024 alongside Q3 and nine-month 2025 earnings reflecting reduced finance costs and ongoing R&D investments, announcing a management cease trade order due to delayed annual filings with expected completion by June 30, 2025, and delisting from the AQSE Growth Market effective April 2, 2025 while maintaining listings on the Canadian Securities Exchange (CSE: MYCO) and OTC (MYCOF).
Noveris Health Sciences Joins the Biotechnology Innovation Organization (BIO)
Noveris Health Sciences Joins Life Sciences BC
Noveris Health Sciences Announces Upcoming AGM and Record Date, and receipt of CSE Notice
Noveris Health Sciences Announces Appointment Of Nathan Mison As Chair Of Advisory Board
Noveris Health Sciences Appoints Geoff Griffiths As Strategic Advisor To Support Commercialization And Growth Initiatives
Noveris Health Sciences Provides Corporate Update
Noveris Health Sciences Provides Corporate Update, and Announces Agreement for Acquisition of Stem Cell Distribution Business
Noveris Health Sciences Inc. Announces Signing Of Market Making Advisory Agreement With DS Market Solutions Inc.
Noveris Health Sciences Inc. Provides Clarifying News Release Regarding Life Offering And Other Disclosure
Noveris Provides Announces Trading Halt Order, And Clarification As To Article
Noveris Announces Closing of Life Offering
Noveris Health Sciences Inc. Unaware Of Any Material Change
Noveris Health Sciences Launches Investor Website and Engages Fairfax Partners Inc. for Investor Relations and Digital Marketing Services
Noveris Announces Resignation Of CEO
Noveris Announces Conversion Of Debentures; Filing Of Early Warning Reports By JJK Holdings Ltd. And Joshua Bartch
JJK Holdings Ltd. Acquires $7,878,792 Convertible Debenture Of Noveris Health Sciences Inc.; Filing Of Early Warning Reports By JJK Holdings Ltd.
Noveris Provides Supplemental Disclosure Regarding Previously Announced Convertible Debenture Issuances
CSE Bulletin: Name and Symbol Change - Mydecine Innovations Group Inc. (MYCO)
CSE Bulletin: Consolidation - Mydecine Innovations Group Inc. (MYCO)
Mydecine Innovations Group Closes Debt Settlements